Aby Buchbinder

5.9k total citations · 1 hit paper
56 papers, 4.2k citations indexed

About

Aby Buchbinder is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Aby Buchbinder has authored 56 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Genetics. Recurrent topics in Aby Buchbinder's work include Chronic Lymphocytic Leukemia Research (9 papers), Cancer therapeutics and mechanisms (8 papers) and HIV Research and Treatment (8 papers). Aby Buchbinder is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Cancer therapeutics and mechanisms (8 papers) and HIV Research and Treatment (8 papers). Aby Buchbinder collaborates with scholars based in United States, France and United Kingdom. Aby Buchbinder's co-authors include Stuart M. Lichtman, Steven L. Allen, Jonathan E. Kolitz, Philip Schulman, Nicholas Chiorazzi, Daniel R. Budman, Tarun Wasil, Franco Fais, Manlio Ferrarini and Vincent Vinciguerra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Aby Buchbinder

55 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

1999 1.9k citations Tarun Wasil, Steven L. Allen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aby Buchbinder United States	26	2.1k	1.6k	1.6k	884	856	56	4.2k
Richard J. Bende Netherlands	27	573 0.3×	1.3k 0.8×	1.0k 0.6×	927 1.0×	472 0.6×	51	3.3k
Carel J.M. van Noesel Netherlands	43	887 0.4×	2.1k 1.3×	2.0k 1.2×	1.6k 1.8×	2.1k 2.5×	118	6.0k
Joseph A. DiGiuseppe United States	31	515 0.2×	1.2k 0.7×	1.0k 0.6×	1.2k 1.3×	1.5k 1.8×	69	4.9k
C. Cameron Yin United States	37	1.7k 0.8×	841 0.5×	1.7k 1.1×	950 1.1×	1.4k 1.7×	226	4.6k
G Jánossy United Kingdom	33	740 0.4×	1.6k 1.0×	459 0.3×	781 0.9×	430 0.5×	59	3.5k
Patricia L. Myskowski United States	33	332 0.2×	1.2k 0.7×	1.7k 1.0×	710 0.8×	1.9k 2.2×	152	4.9k
Mikhail Roshal United States	27	439 0.2×	862 0.5×	532 0.3×	1.4k 1.6×	2.3k 2.7×	103	4.3k
Paul V. O’Donnell United States	35	472 0.2×	1.7k 1.0×	502 0.3×	541 0.6×	1.3k 1.6×	121	4.4k
Neil L. Berinstein Canada	29	582 0.3×	1.3k 0.8×	887 0.6×	792 0.9×	1.1k 1.3×	104	2.9k
Cecilia Sgadari Italy	29	195 0.1×	1.6k 1.0×	540 0.3×	1.3k 1.5×	2.2k 2.6×	68	4.2k

Countries citing papers authored by Aby Buchbinder

Since Specialization

Citations

This map shows the geographic impact of Aby Buchbinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aby Buchbinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aby Buchbinder more than expected).

Fields of papers citing papers by Aby Buchbinder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aby Buchbinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aby Buchbinder. The network helps show where Aby Buchbinder may publish in the future.

Co-authorship network of co-authors of Aby Buchbinder

This figure shows the co-authorship network connecting the top 25 collaborators of Aby Buchbinder. A scholar is included among the top collaborators of Aby Buchbinder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aby Buchbinder. Aby Buchbinder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Degtyarev, Evgeny, Joshua Brody, Aby Buchbinder, et al.. (2024). End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?. Future Oncology. 20(22). 1601–1615. 1 indexed citations

Hijiya, Nobuko, C. Michel Zwaan, Carmelo Rizzari, et al.. (2019). Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. Clinical Cancer Research. 26(4). 812–820. 23 indexed citations

Tian, Xianbin, Hefei Zhang, Tycho Heimbach, et al.. (2018). Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor. The Journal of Clinical Pharmacology. 58(12). 1533–1540. 49 indexed citations

Borad, Mitesh J., Hani M. Babiker, Stephen P. Anthony, et al.. (2015). A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. Cancer Investigation. 33(5). 172–179. 5 indexed citations

Zolla‐Pazner, Susan, Suman Laal, Sherri Burda, & Aby Buchbinder. (2015). Human Monoclonal Antibodies to HIV-1 Define Synergistic Activities Leading to Enhanced Neutralization1. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 46. 38–47.

Raetz, Elizabeth A., D. Morrison, Paul S. Gaynon, et al.. (2013). A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL). Journal of Pediatric Hematology/Oncology. 36(6). 458–463. 34 indexed citations

Patnaik, Amita, Kyriakos P. Papadopoulos, Anthony W. Tolcher, et al.. (2013). Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 71(6). 1499–1506. 44 indexed citations

Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586. 72 indexed citations

Kurzrock, Razelle, Sanjay Goel, Jennifer J. Wheler, et al.. (2012). Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 118(24). 6144–6151. 38 indexed citations

10.

Lambourne, Jonathan, Dan Agranoff, Raoul Herbrecht, et al.. (2009). Association of Mannose‐Binding Lectin Deficiency with Acute Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases. 49(10). 1486–1491. 61 indexed citations

11.

Patnaik, Amita, Chris H. Takimoto, K. Papadopoulos, et al.. (2008). 427 POSTER Pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: a phase I dose-escalation study. European Journal of Cancer Supplements. 6(12). 134–134. 4 indexed citations

12.

Wasil, Tarun & Aby Buchbinder. (2000). Gene Therapy in Human Cancer: Report of Human Clinical Trials. Cancer Investigation. 18(8). 740–746. 4 indexed citations

13.

Lichtman, Stuart M., Steven L. Allen, Daniel R. Budman, et al.. (1999). Acquired factor VIII inhibitors?successful treatment with an oral outpatient regimen. American Journal of Hematology. 60(1). 70–71. 24 indexed citations

14.

Budman, Daniel R., et al.. (1999). A phase I study of sequential vinorelbine followed by paclitaxel. Annals of Oncology. 10(7). 861–864. 11 indexed citations

15.

Huang, Yao, et al.. (1994). Rearrangement and expression of MDM₂ oncogene in chronic lymphocytic leukemia. American Journal of Hematology. 47(2). 139–141. 11 indexed citations

16.

Karwowska, S, Miroslaw K. Górny, Aby Buchbinder, et al.. (1992). Production of Human Monoclonal Antibodies Specific for Conformational and Linear Non-V3 Epitopes of gp120. AIDS Research and Human Retroviruses. 8(6). 1099–1106. 76 indexed citations

17.

Buchbinder, Aby & Alvin E. Friedman‐Kien. (1992). Clinical aspects of Kaposiʼs sarcoma. Current Opinion in Oncology. 4(5). 867–874. 26 indexed citations

18.

Buchbinder, Aby, Steven F. Josephs, D. V. Ablashi, et al.. (1988). Polymerase chain reaction amplification and in situ hybridization for the detection of human B-lymphotropic virus. Journal of Virological Methods. 21(1-4). 191–197. 55 indexed citations

19.

Josephs, Steven F., Dharam V. Ablashi, S. Zaki Salahuddin, et al.. (1988). Molecular studies of HHV-6. Journal of Virological Methods. 21(1-4). 179–190. 52 indexed citations

20.

Yarchoan, Robert, Rose V. Thomas, Jordan Grafman, et al.. (1988). Long-term administration of 3?-Azido-2?,3?-dideoxythymidine to patients with AIDS-related neurological disease. Annals of Neurology. 23(S1). S82–S87. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact